Company: University of Maryland Baltimore
Job title: Professor, Department of Surgery
Dr. Pan Zheng is a Professor at the Department of Surgery in the University of Maryland, Baltimore, and Chief Medical Officer at OncoImmune, Inc.
Dr. Pan Zheng’s research interests are tumor immunology, cancer biology and signal transduction in hematopoietic stem cells (HSC) and cancer stem cells. Her laboratory has been working on TSC-mTOR signaling in rejuvenation of hematopoietic stem cells (HSC) and immunity. Using genetically modified mice with conditionally deletion of hematopoietic lineage cells, they demonstrated that mTOR inhibition is critical to maintain hematopoietic stem cell quiescence. Activation of mTOR in HSC increased mitochondrial biogenesis and elevated levels of reactive oxygen species (ROS). The most important finding with immediate clinical implication is that short-term rapamycin treatment greatly enhanced the efficacy of influenza vaccination in aged mice. Her collaboration with Dr. Yang Liu’s laboratory identified CD24-Siglec signaling pathway in regulating host defense to tissue damage induced inflammation.
Dr. Yang Liu and Dr. Pan Zheng are co-founders and executives in OncoImmune, Inc. The company has completed the Phase II clinical trial on leading product, CD24Fc, for the prevention of acute graft vs host disease for patients undergo hematopoietic stem cell transplantation. The pre-clinical and clinical studies have demonstrated that CD24-Siglec pathway is critical in pathogenesis of autoimmune diseases, metabolic syndrome, non-alcoholic steatohepatitis (NASH), HIV chronic inflammation, and immunotherapy related adverse events (irAE).
CD24-Siglec Signaling Pathway in Regulating Host Defense to Aging & Tissue Damage Related Chronic Inflammation 1:25 pm
day: Day Two